levensten law firm logo

Initial Conference in Pradaxa Multidistrict Litigation set for October 3, 2012

Boehringer Ingelheim is now facing Multidistrict litigation over its dangerous drug, Pradaxa. The Pradaxa litigation was assigned to Chief Judge, David R. Herndon of the Southern District of Illinois. To date, Case Managment Order No. 1, Initial Conference Order and Procedural Matters, setting the initial conference for 10/3/2012 01:30 PM in East St. Louis Courthouse; […]

Profits over Patient Safety: Pradaxa TV Commercials Continue To Flood The Networks

Steps taken by the international pharmaceutical corporation Boehringer Ingelheim pursuant to the development of Pradaxa, an FDA – approved prescription medicine designed to help reduce the risk of stroke in persons with nonvalvular atrial fibrillation, demonstrate the company’s purely profit – driven motivation with respect to the drugs distribution. Moreover, Pradaxa is expected to be […]

Pradaxa Side Effects Outweigh Any Supposed Benefit In Terms of Patient Safety

While Pradaxa, a recently developed oral anticoagulant intended to combat the risk of stroke in patients with atrial fibrillation (AF), was created with an eye to sidestepping many of the limitations associated with Warfarin, Pradaxa’s main competitor, new and potentially more dangerous hazards have arisen with respect to its prescription. Boehringer Ingelheim, the international pharmaceutical […]

Pradaxa riks of bleeding death greater than Warfarin because Pradaxa has no antidote

Despite recent advances in heart patient medications, research has been shown that those prescribed Pradaxa are at greater risk of deadly side effects than risks posed by its predecessor, Warfarin. Intended to prevent strokes in patients with an irregular heartbeat called atrial fibrillation, Pradaxa was designed to circumvent the possibility of brain hemorrhages and other […]

Pradaxa side effects including hemorrhage surpass all drugs monitored by FDA

According to data recently released from QuarterWatch, an Institute for Safe Medication Practices surveillance program which monitors all serious and fatal adverse drug events (ADEs) reported to the Food and Drug Administration through Medwatch, in 2011 the FDA received 179,855 reports of serious or fatal adverse drug reactions. This was an increase of 15,386 reports […]


Your Warriors for Justice
Fight fearlessly. Win strategically.